Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Boehringer Ingelheim
AstraZeneca
Medtronic

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,217,031

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,217,031
Title:Humanized anti-IL-20 antibody and uses thereof
Abstract: The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
Inventor(s): Chang; Ming-Shi (Tainan, TW)
Assignee: National Cheng Kung University (Tainan, TW)
Application Number:14/066,018
Patent Claims:1. A method for treating cancer, comprising administering to a patient in need thereof an effective amount of an humanized antibody capable of binding to human IL-20, the antibody comprises: (i) a heavy chain variable region (V.sub.H), which comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:3 and consists of one or more mutations in one or more framework regions (FRs) in SEQ ID NO:1 or SEQ ID NO:3, and (ii) a light chain variable region (V.sub.L), which comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:5 or SEQ ID NO:7 and consists of one or more mutations in one or more framework regions (FRs) in SEQ ID NO:5 or SEQ ID NO:7 wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, and oral cancer.

2. The method of claim 1, wherein the cancer is breast cancer.

3. The method of claim 1, wherein the V.sub.H comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3.

4. The method of claim 1, wherein the V.sub.L comprises the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:15.

5. The method of claim 3, wherein the V.sub.L comprises the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:15.

6. The method of claim 1, wherein the humanized antibody is a full-length antibody.

7. The method of claim 6, wherein the humanized antibody is an IgG antibody.

8. The method of claim 1, wherein the humanized antibody is an antigen binding fragment.

9. The method of claim 1, wherein the subject in need thereof is a human patient having or suspected of having cancer.

10. The method of claim 1, wherein the subject is co-administered with a second anti-cancer agent.

11. The method of claim 10, wherein the second anti-cancer agent is Tomaxifen, Taxol, Erlotinib, Dexasone, or Herceptin.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Mallinckrodt
McKinsey
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.